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Abstract 
Introduction 
Hepatitis C (HCV) infection in England primarily affects people who inject drugs (PWID). 
We describe persons HCV tested, estimate incidence and establish the cascade of care (CoC) 
for people engaging with drug services. 
Methods  
Persons testing for HCV in drug services in Sentinel Surveillance of Blood Borne Virus 
Testing (SSBBV) between 2008 and 2016 were linked with people attending drug services in 
the National Drug and Treatment Monitoring System (NDTMS). We describe risk 
characteristics, establish the CoC, and estimate HCV incidence in PWID diagnosed in drug 
services. 
Results 
Of 46,721 persons tested for anti-HCV in SSBBV in drug services, 29,773 (63.7%) linked to 
NDTMS. Of these, 9,100 (30.6%) were anti-HCV positive and anti-HCV positivity was 
45.0% in persons reporting urgent housing problems and 43.8% in persons reporting ever 
injecting. Among persons anti-HCV positive, half had ≥1 positive anti-HCV test. For 
persons’ first anti-HCV positive between 2008 and 2013 (n=3123), 74.9% were HCV RNA 
tested, of whom 71.2% were RNA positive, and of these, 14.0% had evidence of interferon-
based treatment, with 52.8% achieving cure. Among PWID, HCV incidence was 8.7 per 100 
person-years (95% CI: 8.1-9.2).  
Conclusion 
Through record linkage of surveillance datasets, we estimated the HCV CoC for people 
attending drug services, providing a benchmark from which to monitor the impact of 
strategies to scale-up prevention, testing, and curative treatment with direct acting antivirals. 
Our study highlights wasteful repeated testing and poor linkage to care for this high risk 
population which need to be addressed.   
Introduction 
In 2018, an estimated 113,000 persons were chronically infected with hepatitis C (HCV) in 
England [1]. These persons are at increased risk of liver cirrhosis, end-stage liver disease 
(ESLD) and hepatocellular carcinoma (HCC). Most HCV infections in the UK are among 
persons who inject drugs (PWID), whether currently, or in the past [2]. Accordingly, for the 
UK to achieve the goal of eliminating HCV as a major public health threat, improvements in 
HCV prevention and treatment in PWID are essential. In 2014, direct acting antivirals (DAA) 
were introduced free of charge to patients in England, initially to those with severe liver 
disease through an expanded access programme, before becoming the NHS standard of care 
from 2015 onwards. DAAs are of shorter treatment duration, better tolerated and more 
effective than previous interferon-based regimens[3].  
Using Sentinel Surveillance of Blood Borne Virus Testing (SSBBV), which collects 
information on all tests regardless of result from collaborating laboratories across England, 
Simmons et al. (2018) estimated the HCV cascade of care (CoC) in the pre-DAA era[4]. An 
estimated 10.4% of persons testing HCV RNA positive within drug services between 2008 
and 2014 received treatment with ribavirin and pegylated interferon, compared to 21.4% 
among persons diagnosed in any setting and 29.4% in those diagnosed in general practice. 
This difference likely reflects the social exclusion and poorer access to care experienced by 
PWID [5].  However, SSBBV has limited demographic, risk factor (eg injecting status and 
missing in 70% of records) and service utilisation information, making it difficult to 
characterise the PWID population, and identify bottlenecks in their care pathway.    
Data on persons attending drug services for problematic drug and alcohol use in England are 
reported to the National Drug Treatment Monitoring System (NDTMS), and indicate that 
65.7% of people eligible [6] (ever injected drugs) self-reported being HCV tested, 81.5% 
among person with evidence of injecting drug use (IDU) [7]. However, data on HCV 
positivity, linkage to care and outcome from HCV treatment in this population is limited.  
Linkage between the two surveillance systems provides an opportunity to better understand 
people who are tested, and positive, for HCV in specialist drug services, their associated risk 
factors and HCV treatment outcomes. Of particular importance is describing the CoC from 
diagnosis to treatment outcome, so that we can improve, and provide more detail on, the pre-
DAA baseline CoC estimates gained from Simmons et al in this vulnerable population, with 
additional information held by NDTMS.  
Methods 
Data sources 
Public Health England’s (PHE) SSBBV testing collects information on hepatitis A-E, HIV 
and HTLV positive and negative tests, patient demographics and the service requesting the 
tests, from 23 participating sentinel laboratories in England [8]. Data from the participating 
laboratory information systems are extracted and records of individuals are deduplicated and 
linked to all other test results using a combination of Soundex (phonetic algorithm for 
indexing names), date of birth, NHS number and hospital number. Limited risk factor 
information is available. 
PHE’s NDTMS collects data on treatment delivery for problematic drug and alcohol use, 
through community-based, outpatient and inpatient settings, in England, covering all 
publically funded treatment (approximately 900 sites in 2017). Specialist drug services 
provide demographic and clinical information on persons receiving treatment for drug and 
alcohol addiction, the interventions delivered to them and outcomes. NDTMS does not 
collect information on persons who use drug and alcohol services but are not being treated for 
their addiction,e.g. needle and syringe programmes (NSP).  
Data Linkage 
Personal identifiers within NDTMS are limited, but include initials, date of birth, sex, and 
drug and alcohol action team (DAT) of residence and treatment. DATs are multiagency 
partnerships responsible for coordinating local initiatives and programs on drug and alcohol 
use. All persons (1,095,944 as of December 2017) in NDTMS are required to have these 
identifiers, and were matched to persons in SSBBV who were tested in drug services and had 
the corresponding information (initials, date of birth, sex and location of test as minimum). 
As there were no additional variables available to identify the correct match, only one-to-one 
matches were accepted; where more than one NDTMS client matched to the same SSBBV 
persons, none were retained. 
For linked persons, all anti-HCV and HCV RNA testing data (including testing outside of 
drug services) were extracted from SSBBV. Patient demographics, risk factors and drug 
history were extracted from NDTMS. Persons anti-HCV tested in drug services in SSBBV 
between 2008 and 2016 were included in analysis. History of injecting drug use was assigned 
based on information from SSBBV and/or NDTMS. The drugs used by persons were 
classified according to a hierarchy, with opiates being recorded over non-opiate drug use and 
co-addiction with alcohol being recorded over no problems with alcohol. 
Cascade of care 
SSBBV allows an estimation of the CoC, where sequential HCV RNA tests during a 390-day 
period, indicative of treatment monitoring, are used to identify persons who received 
treatment with ribavirin and pegylated interferon, with a final negative PCR indicative of 
viral clearance. This methodology has been validated against a clinical database and used by 
Simmons et al. (2018) [4,9].  
We estimated interferon-based treatment rates for persons first diagnosed between 2008 and 
2013 in drug services, the years during which treatment could be monitored using the SSBBV 
sequential PCR algorithm, and treated up to end-2014, after which DAAs became the most 
common treatment regimen. The CoC was estimated for persons with a history of injecting 
drug use, opiate use (with and without alcohol misuse), urgent housing problems and multiple 
positive anti-HCV tests in drug services and compared. 
Statistical Analysis 
Statistical analysis was carried out in STATA SE (version 15), with Chi-squared test being 
used to compare categorical variables and Wilcoxon rank-sum tests to compare continuous 
variables.  
Using logistic regression models, we examined predictors of testing positive for HCV, 
regardless of setting of positive test, between 2008 and 2016, using the following variables: 
age, sex, ethnicity, drug type, alcohol use, history of injecting drug use, and housing status. 
Only variables found to be significant (p <0.05) were included within the final model. Two-
way interactions were examined. 
Overall (2008-2016 inclusive) and three-year rolling incidence of HCV was calculated for all 
persons, and persons with a history of injecting drug use, who had at least two anti-HCV tests 
within each three-year period, regardless of location of tests, between 2008 and 2016 in 
SSBBV. For persons with two negative test results, their two most recent negative tests were 
used to calculate follow-up time in person-years; for persons who tested positive, follow-up 
time in person-years was calculated from their last negative test date till their first positive 
test date . When estimating incidence by age group, age was based on the first negative test 
used to calculate follow-up time. 95% confidence intervals were calculated using the Poisson 
distribution.  
  
Results 
Between 2008 and 2016, 46,721 persons in SSBBV were identified as having had anti-HCV 
testing in drug services. Median age at test was 36 years (Interquartile range (IQR): 30-42 
years), and 70.5% (32,961) were male. Of those, 12,249 (26.2%) were anti-HCV positive, 
and 7,171 (58.5%) were RNA positive during this period. Complete identifiers were available 
for 87.5% (40,921), of which 72.8% (29,773) linked to NDTMS. There was little difference 
between persons who did and did not link to NDTMS by sex and age, however a lower 
proportion of records were linked among those 14-29 years and 50 years and older, compared 
with other age groups (see supplementary table 1).  
Characteristics of linked persons tested for HCV in drug services 
Of linked persons (29,773), the median age at HCV test was 36 years (IQR: 30-42 years), 
with men accounting for 72.1% and 66.0% reporting having ever injected drugs (table 1). At 
least one drug treatment episode starting between 2008 and 2016 was reported for 28,597 
(96.1%) , with a median of 3 (IQR: 2-5) treatments over the period. The remaining 1,176, 
were treated outside the 2008-2016 study period.  
Anti-HCV positivity was 30.6% (9,100) over the period (table 1), 95.3% (8,668) of whom 
tested positive within drug services in SSBBV, with the remainder mostly tested in general 
practice (123) or prison services (81). The median age at first positive HCV test was 38 years 
(IQR: 32-44 years), and positivity was highest among persons who reported an urgent 
housing problem (45.0%), who had ever injected drugs (43.8%) and reported ever having a 
problem with opiates and alcohol (42.5%).  
Among those anti-HCV positive (9,100), 7,036 had a HCV RNA test in SSBBV between 
2008 and 2016, with a further 333 being tested outside this period. The majority (4,936) had 
two or more HCV RNA test between 2008 and 2016 (median: 2; IQR: 1-4). Over the period, 
5,208 (74.0%) were positive at any stage and 3,927 (55.8%) were positive on their last HCV 
RNA test. 
Among persons with no reported IDU, 4.7% (n=478) were anti-HCV positive. When 
compared to persons with IDU reported, a higher proportion were female, (36.0% vs 28.0; 
p<0.001), and persons were older at first diagnosis (regardless of setting) (40 years vs 36 
years, p<0.001). However, 80.5% (n=385) reported history of opiate use. Where route of drug 
use was known (452), only 17 persons reported having snorted drugs.  
Cascade of Care for HCV 
Of linked persons, 16,707 were tested for anti-HCV in drug services between 2008 and 2013, 
the years the treatment algorithm can monitor pre-DAA treatment, and 3,123 were diagnosed 
as HCV positive for the first time. By 2014, 2,340 (74.9%) were HCV RNA tested, 1,666 
(53.3%) were HCV RNA positive, 233 (7.5%) were treated, and 123 (3.9%) achieved SVR 
(Figure 1).  Similar treatment rates were observed for persons who had ever injected drugs, 
misused opiates only, misused opiates and alcohol and who had urgent housing problems 
(supplementary table 2). However, a higher proportion of persons were treated when there 
was a record of multiple positive tests in drug services (11.9%).   
Predictors of anti-HCV positivity  
Persons had higher odds of ever testing positive (in any setting) for anti-HCV with increasing 
age (per 10 year increase in age: adjusted odds ratio (aOR): 1.59; 95% confidence interval 
(CI): 1.53-1.65), female sex (aOR: 1.32; 95% CI:1.23-1.41), ever injected drugs (aOR: 10.64; 
95% CI: 9.43-12.01), a housing problem reported (housing problem: aOR: 1.12; 95% CI: 
1.04-1.21; urgent housing problem: aOR: 1.82; 95% CI: 1.68-1.97), reported opiate misuse 
(aOR: 3.95; 95% CI: 3.18-4.91) and reported alcohol misuse (aOR: 1.09; 95% CI: 1.03-1.16) 
(table 2). Persons had lower odds of testing positive if they were Asian (aOR: 0.34; 95% CI: 
0.27-0.43) or black (aOR: 0.77; 95% CI: 0.61-0.97) when compared to persons of white 
ethnicity. 
Multiple HCV testing  
Between 2008 and 2016, 23.8% (7,072/29,773) persons tested had more than one anti-HCV 
test within drug services (regardless of result), with an average of 1.4 tests per person, 
equating to 40,245 anti-HCV tests reported to SSBBV (range: 1-13). The positivity of these 
tests was 29.5% (11,884). 
Among those anti-HCV positive, half (50.8%, n=4625) had more than one positive HCV test 
reported to SSBBV from any setting between 2008 and 2016 (median 2.0 tests per person), 
and 2288 persons had more than one positive test result within drug services. An additional 
positive test prior to this period (2002 (start of SSBBV) and 2007) was reported to SSBBV 
for 1,593 (18.4%) persons, of which 26.7% had their first positive HCV test in drug services, 
21.0% in general practice and 11.9% in prison.   
HCV Incidence 
Among persons anti-HCV negative between 2008 and 2016 (21,765), 8,452 had more than 
one HCV test conducted during this period, a median of 1.6 years (IQR: 0.8-3.0 years) apart. 
Of persons with two tests, 14.0% (1,092) subsequently tested anti-HCV positive, equivalent 
to an estimated anti-HCV incidence of 6.3 per 100 person years (95% CI: 5.9-6.7). For 
persons with a history of injecting drug use (n=5,801) the estimated incidence was 8.7 per 
100 person years (95% CI: 8.1-9.2) and was 11.9 per 100 person years (95% CI: 10.7-13.1) in 
persons who reported urgent housing problems. Incidence was lower in older age groups; 8.4 
per 100 person years (95% CI: 7.6-9.2) in persons aged 14-29, 6.0 per 100 person years (95% 
CI: 5.4-6.5) in persons 30-39 years, 5.0 per 100 person years (95% CI: 4.3-5.8) in persons 40-
49 and 2.8 per 100 person years (95% CI: 1.7-4.1) in persons 50 years and older. Three-year 
rolling incidence rates in persons who have ever injected drugs are presented in figure 2, with 
an average three-year rolling incidence of 9.3 per 100 person years.  
Discussion 
Main findings 
Between 2008 and 2016, 31% of persons tested in drug services and reported to SSBBV were 
anti-HCV positive; 95.3% were first reported anti-HCV positive through drug services and 
4.7% in other services. Persons diagnosed positive were more likely to be female and have 
reported injecting drug use, opiate use, alcohol use, and housing problems. Half of persons 
anti-HCV positive had multiple positive test results reported to SSBBV, on average 2.0 per 
person, 18% had been diagnosed with HCV prior to 2008. HCV treatment with ribavirin and 
pegylated interferon between 2008 and 2013 was low, at 14.0% of persons HCV RNA 
positive. HCV incidence was estimated to be 8.7 per 100 person years in people who report 
IDU. 
Limitations 
For the first time we linked SSBBV and NDTMS, two routinely collected surveillance 
datasets, providing a large sample of persons attending drug services for analysis. SSBBV 
covers approximately 40% of all HCV testing, providing representative data to monitor HCV 
infection and the cascade of care of diagnosed persons, and NDTMS has enriched testing data 
with demographic and risk characteristics of the PWID population. The low matching rate 
(64% of SSBBV drug tests) with NDTMS may partly be explained by PWID who use NSP 
and are tested for HCV, but have never initiated treatment (and so not included in NDTMS) 
and the strict matching criteria that was required. We do not know how linked and unlinked 
persons differ but demographics for opiate users in our linked data and annual NDTMS 
reports are similar [10]. In addition, positivity rates for PWID are similar in our linked data 
and the Unlinked Anonymous (UAM) Survey of people in contact with drug services [11].  
Further, since 2014 some testing at drug clinics will be missed if persons were only tested 
with dried blood spot (DBS) testing and processed by commercial laboratories who have 
inconsistently reported to SSBBV. NDTMS does not collect information on PWID who use 
NSP but have never accessed treatment for their drug or alcohol problems. How they differ 
from our cohort in unknown but they are more likely to contain recent injecting initiates, 
active injectors and injectors with more chaotic lifestyles, who are at increased risk of 
acquiring and transmitting HCV [12]. This could explain why fewer persons aged 14-29 
years in SSBBV were linked. Monitoring incidence and re-infection in this actively injecting 
population through improved data collection and surveillance systems is therefore important. 
Additionally, while the treatment monitoring algorithm is highly specific and sensitive at 
detecting treatment, estimates may be an underestimate if the testing to monitor treatment 
was processed by laboratories outside the SSBBV network. 
Other evidence and implications 
With the enhanced information provided through linkage with NDTMS, we were able to look 
at the CoC in sub-sets of the HCV diagnosed population attending drug services and provide 
stronger evidence of the CoC estimates for this population by Simmons et al. (2018)[4]. 
While we were unable to look at CoC stage prior to anti-HCV testing (the proportion of at 
risk persons in drug treatment), NDTMS data suggests testing rates of eligible PWID in drug 
treatment have improved over recent years, increasing from 57% of persons receiving an 
HCV test in 2009-10 to 83% in 2015-16[13].  
The low treatment rates estimated through the CoC are sub-optimal for this population, and 
lower than Simmons et al. found in all HCV diagnosed persons overall (21.4%), reflecting 
the inequalities experienced by this vulnerable population. While annual testing in drug 
services may be recommended by NICE, our findings show multiple positive anti-HCV tests 
(median: 2), both within and outside drug services, with suboptimal translation into 
treatment. It is important to note that although treatment uptake was low regardless of the 
number of positive tests, there was a higher proportion treated among those with multiple 
positive tests. This indicates a problem in confirmatory testing and subsequent engagement in 
care, rather than simply in the identification of anti-HCV positive persons, and represents 
inefficiencies in the diagnosis to treatment pathway. It is likely that due to limited DBS 
testing coverage in SSBBV, we are underestimating the amount of repeat positive anti-HCV 
testing. Challenges in linkage to care have also been observed in emergency department 
testing initiatives, where Parry et al. [14] found it 6 times more difficult to engage HCV 
diagnosed persons in care than persons diagnosed with hepatitis B or HIV. Our study 
reinforces recommendations for services to be patient focused, community-based and as close 
to a single-step pathway as possible. It is anticipated that the introduction of DAAs and the 
pressure on lead clinicians in hospitals to meet NHS England treatment targets (“run rates”), 
as well as the need to treat active PWIDs in order to achieve WHO elimination targets, will 
help reduce the system and structural barriers to treatment [15]. Coverage of opiate substitute 
therapy (OST) and NSP still needs to be maintained, as modelling has suggested that OST 
and high coverage of NSP can reduce HCV acquisition risk by 50% and 76% respectively in 
Europe [16]. 
We found predictors of a positive anti-HCV test at any time in the study period included 
being female, increasing age, ever injecting drugs, opiate use, alcohol misuse and housing 
problems.  This corroborates the findings of similar studies, with positivity associated with 
female sex, identified risk behaviours associated with HCV infection being more frequently 
reported in women, including pooling with others to buy drugs, heroin use and reusing and 
sharing drug taking paraphernalia (including cookers and syringes) [17–19]. Furthermore, the 
UAM survey in England has consistently found higher reported rates of sharing needles and 
syringes in females [20]. Anti-HCV positivity was also associated with housing problems; 
which have been associated with higher rates of risk behaviours, such as public injecting and 
sharing of injecting equipment, in UAM data [21], along with other studies [22–24]. Were we 
able to adjust for these risk behaviours the observed difference by gender and housing status 
may have been diminished. 
Whilst the majority of persons HCV positive had a documented injecting history (95%), there 
was a substantial amount of testing in persons not reporting injecting (34%), with associated 
anti-HCV positivity at 4.7%. This is double that found in opt-out emergency department 
testing studies, which are being evaluated as a way of identifying undiagnosed persons 
[14,25]. It is possible that these persons did not disclose or recognise previous IDU; 
alternatively, other risk factors, such as blood transfusion, sexual transmission, sharing 
paraphernalia used to snort drugs, tattooing or needlestick injuries may have contributed to 
their HCV status. The substantial proportion of anti-HCV positive individuals in non-
injectors suggests that routine HCV testing of all drug service attendees may be of value in 
identifying persons who might not otherwise be diagnosed with HCV. 
Previous estimates of HCV incidence for persons attending drug services and PWID have 
varied quite widely, and a literature review by Wiessing et al. [26] found UK estimates to be 
between 2.7 and 42 HCV infections per 100 person years (mean: 14), likely reflecting not 
only the heterogeneity of risk (by demographic and risk factors) in PWID, but also the 
methodological challenges in assessing incidence in this population and setting. More 
recently, Hope et al. [27] estimated incidence to be 12.3 per 100 person years using data from 
the 2011-2013 UAM surveys. Through record linkage, we have estimated incidence at 8.7 per 
100 person years in PWID between 2008 and 2016, slightly lower than the mean in Wiessing 
et al and Hope et al. In the future, with improved coverage of DBS testing, data linkage could 
provide an alternative approach through which to estimate HCV incidence in PWID- and 
important metric for measuring progress towards the WHO elimination goal. 
Conclusion 
By linking routinely collected surveillance data on HCV testing and people attending 
specialist drug services, we found that problem drug users are frequently tested but the 
linkage to HCV treatment and care is poor. Our study established a baseline HCV treatment-
rate for interferon-based therapies in persons receiving treatment for drug addiction. 
Worryingly, overall treatment uptake is suboptimal among this population, with evidence of 
treatment where multiple positive HCV tests had occurred. Drug services need to provide 
community-based, patient-focused, streamlined testing and treatment pathways, to reduce the 
health inequalities experienced by drug service users, particularly those more vulnerable, 
such as women and homeless persons. Robust monitoring of the CoC using data linkage 
approaches should continue to ensure that PWID have equitable access to DAAs in 
appropriate settings. 
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Table 1: Characteristics of persons linked to NDTMS and tested for anti-HCV between 2008 and 
2016 in drug services in England. Positivity is presented for tests within drug services only (within 
parentheses) and where positive in any setting in SSBBV.  
   
N (in drug service) 
percent (in drug 
services)
Total 29,773 9,100 (8,668) 30.6 (29.1)
Sex
Male 21,471 6,514 (6,223) 30.3 (29.0)
Female 8,302 2,586 (2,445) 31.1 (29.5)
Age $
14-29 years 7,024 1,430 (1,287) 20.4 (18.3)
30-39 years 12,310 3,877 (3,689) 31.5 (30.0)
40-49 years 8,082 2991 (2,906) 37.0 (36.0)
50+ years 2,356 802 (786) 34.0 (33.3)
Ethnicity
White 25,538 8,153 (7,771) 31.9 (30.4)
Black 650 130 (125) 20.0 (19.2)
Asian 1,114 95 (93) 8.5 (8.3)
Other 949 272 (253) 28.7 (26.7)
Not reported 1,522 450 (426) 29.6 (28.0)
Nationality
British 26,946 8,300 (7,891) 30.8 (29.3)
European 697 276 (273) 39.6 (39.2)
Other 560 106 (102) 18.9 (18.2)
Not reported 1,570 418 (402) 26.6 (25.6)
Drug
Opiate plus Alcohol 8,449 3,593 (3,405) 42.5 (40.3)
Opiate 13,989 5,184 (4,960) 37.1 (35.5)
Non-opiate plus Alcohol 3,039 127 (119) 4.2 (3.9)
Non-opiate only 1,466 74 (68) 5.0 (4.6)
Alcohol only 2,830 122 (116) 4.3 (4.1)
Ever Injected
Yes 19,664 8,622 (8,221) 43.8 (41.8)
No 10,109 478 (447) 4.7 (4.4)
Housing status*
Urgent housing problem1 4,947 2,228 (2,085) 45.0 (42.1)
Housing problem2 6,305 1,997 (1,904) 31.7 (30.2)
No housing problem 16,935 4,308 (4,134) 25.4 (24.4)
Not reported 1,586 567 (545) 35.8 (34.4)
Sexuality^
Heterosexual 9,675 2,948 (2,808) 30.5 (29.0)
Homosexual 155 34 (32) 21.9 (20.6)
Other 181 53 (50) 29.3 (27.6)
Not Reported 19,762 6,065 (5,778) 30.7 (29.2)
Region $
East Midlands 906 216 (197) 23.8 (21.7)
London 3,671 932 (903) 25.4 (24.6)
North East 4,404 925 (849) 21.0 (19.3)
North West 7,771 3,357 (3,235) 43.2 (41.6)
South East 1,435 372 (340) 25.9 (23.7)
South West 2,818 798 (752) 28.3 (26.7)
West Midlands 1,683 450 (440) 26.7 (26.1)
Yorkshire and Humber 7,085 2,050 (1,952) 28.9 (27.5)
Treated for alcohol or drug misuse between 2008-2016
Yes 28,597 8,623 (8,211) 30.2 (28.7)
No 1,176 477 (457) 40.6 (38.9)
anti-HCV positive in any setting
$ at time of first anti-HCV test between 2008-2016; £ vaccinated up to end 2016; * worst housing status between 2008 and 2016;  ^
collected from 2016; 1 Lives on the streets, used night hostels or sleeps on different friends floor each night; 2 short term guest with 
friends/family, uses night winter shelter, direct access short stary hostel or short term B&B.
Number tested
 Table 2: Multivariable logistic regression to examine factors associated with ever testing positive for 
anti-HCV (in any setting) for persons linked between SSBBV and NDTMS. 
  
 
 
 
 
 
 
 
adjusted odds 
ratio
95% 
confidence 
interval
p-value
Sex
Male 1
Female 1.32 1.23-1.41
Ethnicity
White 1
Asian 0.34 0.27-0.43
Black 0.77 0.61-0.97
Other 1.03 0.87-1.22
Age ^
per 10 year increase 1.59 1.53-1.65 <0.001
Ever injected drugs
No 1
Yes 10.64 9.43-12.01
Drug misused*
None reported 1
Non-opiate 0.76 0.59-0.99
Opiate 3.95 3.18-4.91
Alcohol misuse
No 1
Yes 1.09 1.03-1.16
Housing status £
No housing problem 1
Housing problem 1.12 1.04-1.21
Urgent housing problem 1.82 1.68-1.97
0.005
<0.001
*exclus ive groups  where opiate misuse categorised over non-opiate misuse; ^age 
at fi rs t test between 2008 and 2016; £ worst hous ing s tatus  between 2008 and 2016
<0.001
<0.001
<0.001
<0.001
Figure 1: The cascade of care, in the era of ribavirin and pegylated interferon treatment, for persons 
tested for anti-HCV in drug services between 2008 and 2013, followed up to 2014, and linked to 
NDTMS in England 
 
 
Figure 2: Three-year rolling incidence of anti-HCV in persons who have ever injected drugs 
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